塔綠班真的不愧是塔綠班，人家高端自己都講了，我這篇論文沒有保護力的相關資料喔！
但是塔綠班還是可以很爽高潮，笑死。
高端也講了，他這個是在中和抗體最高的時候量的資料，但是中和抗體變少之後，就要看
t細胞會不會起到對付變種的作用，但他們自己也不清楚，可是塔綠班已經覺得高端是神
藥，在那邊爽歪歪，北七！
A limitation of our study is that the sera were taken 4 weeks after the second
shot of MVC-COV1901 when immunity has peaked and only just started to wane. T
herefore, we could not evaluate the impact of waning immunity on the neutraliz
ing capacity against the variants. The study cannot evaluate the role of T-cel
l responses elicited by the vaccine as it was reported that the T-cell respons
es to immunization may confer heterotypic coverage and are less affected by Vo
Cs [31].
COVID-19 vaccines in phase 3 clinical trials in South Africa when the Beta var
iant became predominant showed considerably high protection against severe cli
nical endpoints, while overall efficacy is lower than at sites outside of Sout
h Africa [32].
Since there are no correlates options of protection being published for emergi
ng variants, it warrants further study on how the reduced neutralizing titers
will translate to clinical endpoints. We are currently conducting a randomized
, double-blind, placebo-controlled phase 2 study for safety and immunogenicity
of MVC-COV1901 with >3800 subjects (NCT04695652). The samples from the phase
2 trial would allow us to further investigate the effects of variants on neutr
alizing titers by using a larger set of samples and newer variants.